Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 13

1.

Differential Response Following Infection of Mouse CNS with Virulent and Attenuated Vaccinia Virus Strains.

Israely T, Paran N, Erez N, Cherry L, Tamir H, Achdout H, Politi B, Israeli O, Zaide G, Cohen-Gihon I, Vitner EB, Lustig S, Melamed S.

Vaccines (Basel). 2019 Feb 12;7(1). pii: E19. doi: 10.3390/vaccines7010019.

2.

Delineating pathological pathways in a chemically induced mouse model of Gaucher disease.

Vardi A, Zigdon H, Meshcheriakova A, Klein AD, Yaacobi C, Eilam R, Kenwood BM, Rahim AA, Massaro G, Merrill AH Jr, Vitner EB, Futerman AH.

J Pathol. 2016 Aug;239(4):496-509. doi: 10.1002/path.4751. Epub 2016 Jul 5.

PMID:
27234572
3.

Induction of the type I interferon response in neurological forms of Gaucher disease.

Vitner EB, Farfel-Becker T, Ferreira NS, Leshkowitz D, Sharma P, Lang KS, Futerman AH.

J Neuroinflammation. 2016 May 12;13(1):104. doi: 10.1186/s12974-016-0570-2.

4.

Innate immune responses in the brain of sphingolipid lysosomal storage diseases.

Vitner EB, Futerman AH, Platt N.

Biol Chem. 2015 Jun;396(6-7):659-67. doi: 10.1515/hsz-2014-0301. Review.

PMID:
25720063
5.

Emerging therapeutic targets for Gaucher disease.

Vitner EB, Vardi A, Cox TM, Futerman AH.

Expert Opin Ther Targets. 2015 Mar;19(3):321-34. doi: 10.1517/14728222.2014.981530. Epub 2014 Nov 21. Review.

PMID:
25416676
6.

RIPK3 as a potential therapeutic target for Gaucher's disease.

Vitner EB, Salomon R, Farfel-Becker T, Meshcheriakova A, Ali M, Klein AD, Platt FM, Cox TM, Futerman AH.

Nat Med. 2014 Feb;20(2):204-8. doi: 10.1038/nm.3449. Epub 2014 Jan 19.

PMID:
24441827
7.

Neuronal accumulation of glucosylceramide in a mouse model of neuronopathic Gaucher disease leads to neurodegeneration.

Farfel-Becker T, Vitner EB, Kelly SL, Bame JR, Duan J, Shinder V, Merrill AH Jr, Dobrenis K, Futerman AH.

Hum Mol Genet. 2014 Feb 15;23(4):843-54. doi: 10.1093/hmg/ddt468. Epub 2013 Sep 24.

8.

Neuronal forms of Gaucher disease.

Vitner EB, Futerman AH.

Handb Exp Pharmacol. 2013;(216):405-19. doi: 10.1007/978-3-7091-1511-4_20. Review.

PMID:
23563668
9.

Contribution of brain inflammation to neuronal cell death in neuronopathic forms of Gaucher's disease.

Vitner EB, Farfel-Becker T, Eilam R, Biton I, Futerman AH.

Brain. 2012 Jun;135(Pt 6):1724-35. doi: 10.1093/brain/aws095. Epub 2012 May 7.

PMID:
22566609
10.

Animal models for Gaucher disease research.

Farfel-Becker T, Vitner EB, Futerman AH.

Dis Model Mech. 2011 Nov;4(6):746-52. doi: 10.1242/dmm.008185. Epub 2011 Oct 4. Review.

11.

Spatial and temporal correlation between neuron loss and neuroinflammation in a mouse model of neuronopathic Gaucher disease.

Farfel-Becker T, Vitner EB, Pressey SN, Eilam R, Cooper JD, Futerman AH.

Hum Mol Genet. 2011 Apr 1;20(7):1375-86. doi: 10.1093/hmg/ddr019. Epub 2011 Jan 20.

PMID:
21252206
12.

Altered expression and distribution of cathepsins in neuronopathic forms of Gaucher disease and in other sphingolipidoses.

Vitner EB, Dekel H, Zigdon H, Shachar T, Farfel-Becker T, Eilam R, Karlsson S, Futerman AH.

Hum Mol Genet. 2010 Sep 15;19(18):3583-90. doi: 10.1093/hmg/ddq273. Epub 2010 Jul 8.

PMID:
20616152
13.

Common and uncommon pathogenic cascades in lysosomal storage diseases.

Vitner EB, Platt FM, Futerman AH.

J Biol Chem. 2010 Jul 2;285(27):20423-7. doi: 10.1074/jbc.R110.134452. Epub 2010 Apr 29. Review.

Supplemental Content

Loading ...
Support Center